# Cas9 Endonuclease: Streptococcus pyogenes CRISPR System, HNH/RuvC Cleavage, and Target Specificity ## Key Takeaways - *Streptococcus pyogenes* Cas9 (SpyCas9) is a dual-nuclease RNA-guided DNA endonuclease essential for the type II-A CRISPR-Cas adaptive immune system, cleaving foreign DNA via its HNH and split RuvC domains to generate blunt double-strand breaks (DSBs) 3 bp upstream of a 5'-NGG-3' Protospacer Adjacent Motif (PAM). - The protein exhibits a bilobed architecture comprising a Recognition (REC) lobe for RNA/DNA binding and a Nuclease (NUC) lobe containing the catalytic HNH and RuvC domains, with the PAM-interacting (PI) domain at the C-terminus dictating PAM specificity. - SpyCas9 functions within a cascade involving crRNA-tracrRNA duplex formation, R-loop generation upon target DNA binding, and conformational activation of its nuclease domains, a process that can be inhibited by bacteriophage-encoded anti-CRISPR (Acr) proteins like AcrIIA4 and AcrIIA5. - Clinical translation of SpyCas9 for genome editing is significantly challenged by pre-existing human immunity, with up to 78% of individuals possessing anti-Cas9 antibodies, necessitating the use of alternative Cas9 orthologs or engineered variants to mitigate immune clearance. - Engineered Cas9 variants, such as catalytically dead Cas9 (dCas9) and those with altered PAM specificity (e.g., xCas9), are critical tools for gene editing, transcriptional modulation, and base editing, while small-molecule inhibitors are being developed to reduce off-target cleavage. --- ## Executive Summary & Key Metadata The *cas9* gene of *Streptococcus pyogenes* (SpyCas9) encodes a large, multi-domain RNA-guided DNA endonuclease that constitutes the effector nuclease of the type II-A CRISPR-Cas adaptive immune system. This enzyme is responsible for the recognition and cleavage of foreign nucleic acids, primarily bacteriophage genomes and conjugative plasmids, in a sequence-specific manner directed by a single-guide RNA (sgRNA) and a trans-activating CRISPR RNA (tracrRNA) duplex. The protein is a dual-nuclease architecture, containing an HNH domain that cleaves the target DNA strand and a split RuvC domain that cleaves the non-target strand, generating a blunt double-strand break (DSB) three base pairs upstream of the protospacer adjacent motif (PAM). The repurposing of SpyCas9 as a programmable genome-editing tool has revolutionized molecular biology, enabling precise gene knockouts, base editing, prime editing, and transcriptional modulation in virtually all model organisms. Its clinical translation, however, is constrained by off-target effects, immunogenicity, and the requirement for a specific PAM sequence (5'-NGG-3'). This manual provides a comprehensive, biophysically rigorous examination of the *cas9* gene, from its genomic architecture and structural biology to its clinical relevance, [pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), and bioinformatic resources. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | cas9 (not officially assigned; bacterial gene) | | **UniProt Accession** | Q99ZW2 | | **Representative PDB ID** | 4OO8 | | **Chromosomal Locus** | *S. pyogenes* M1 GAS genome: Spy_1046 (NC_002737.2) | | **Primary Molecular Function** | RNA-guided site-specific DNA endonuclease; DSB generation | | **Disease & Pathology Associations** | Not a human oncogene; implicated in bacterial virulence; therapeutic target for gene therapy; immunogenic in human hosts | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Genomic Context in *Streptococcus pyogenes* The *cas9* gene (locus tag Spy_1046) is situated within the type II-A CRISPR-Cas locus of the *S. pyogenes* M1 GAS (SF370) genome, a circular chromosome of approximately 1.85 Mb. The locus is organized as a canonical operon: *cas9*, *cas1*, *cas2*, and *csn2*, followed by the CRISPR array. The gene is 4,107 base pairs in length, encoding a protein of 1,368 amino acids with a predicted molecular weight of ~158 kDa. The promoter region upstream of *cas9* contains a canonical -10 and -35 box recognized by the housekeeping sigma factor σ^A, and its expression is constitutive but upregulated upon phage infection via a cyclic-di-AMP (c-di-AMP) dependent pathway. The genomic organization is as follows: ``` 5' - [Promoter] - cas9 (4107 bp) - cas1 - cas2 - csn2 - [CRISPR Array] - 3' ``` The CRISPR array itself is composed of a series of direct repeats (DRs) of 30 nucleotides interspersed with unique spacer sequences of 30-34 nucleotides. These spacers are derived from prior phage infections and serve as the memory bank for adaptive immunity. The transcription of the array yields pre-crRNA, which is processed into mature CRISPR RNAs (crRNAs) by the combined action of tracrRNA, RNase III, and Cas9 itself. ### 1.2 Promoter Architecture and Transcriptional Regulation The *cas9* promoter (P_cas9) is a strong constitutive promoter. DNase I footprinting and electrophoretic mobility shift assays (EMSAs) have identified a binding site for the global transcriptional regulator CodY, which represses *cas9* expression during exponential growth in rich media. Conversely, the stringent response alarmone (p)ppGpp, produced during amino acid starvation, relieves this repression, linking CRISPR-Cas activity to nutritional stress. Additionally, the promoter contains a binding site for the CcpA catabolite control protein, which mediates carbon catabolite repression, further integrating the system into central metabolism. ### 1.3 Isoforms and Post-Transcriptional Processing Unlike eukaryotic genes, *cas9* does not undergo alternative splicing. However, post-transcriptional regulation occurs via the differential processing of the polycistronic mRNA. The primary transcript is processed by RNase III, which cleaves the duplex formed between the tracrRNA and the pre-crRNA. This processing yields a mature tracrRNA (89 nt) and a crRNA (39-42 nt) that remain base-paired. This RNA duplex is then loaded into the Cas9 apoenzyme. A minor isoform of the protein, lacking the first 15 amino acids, has been detected by mass spectrometry, likely arising from an alternative translation start site at Met16. This N-terminally truncated isoform retains full catalytic activity *in vitro*, suggesting the extreme N-terminus is not essential for folding or function. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Topology The SpyCas9 protein is a bilobed architecture composed of two main lobes: the recognition (REC) lobe and the nuclease (NUC) lobe. The REC lobe is primarily responsible for binding the sgRNA and the target DNA, while the NUC lobe contains the catalytic residues. The two lobes are connected by a flexible arginine-rich bridge helix (BH). High-resolution crystal structures (PDB: 4OO8, 4UN3, 5F9R) have resolved the protein in multiple conformational states: apo (unbound), sgRNA-bound, and ternary (sgRNA-DNA) complexes. The domain architecture from N-terminus to C-terminus is as follows: 1. **Recognition Lobe (REC)** - **Arg-Rich Bridge Helix (BH):** Residues 60-93. A long alpha-helix that connects the REC and NUC lobes and is critical for PAM duplex recognition. - **REC1 Domain:** Residues 94-179 and 308-713. A large alpha-helical domain that interacts with the repeat:anti-repeat duplex of the sgRNA. - **REC2 Domain:** Residues 180-307. A smaller helical domain that stabilizes the sgRNA seed region. - **REC3 Domain:** Residues 714-780. A topoisomerase-homology domain that interacts with the sgRNA:DNA heteroduplex. 2. **Nuclease Lobe (NUC)** - **RuvC-I Domain:** Residues 1-59. Contains the N-terminal half of the split RuvC nuclease domain. - **HNH Domain:** Residues 780-906. A nuclease domain structurally homologous to the HNH endonucleases (e.g., colicin E7). It is inserted within the RuvC-II domain. - **RuvC-II Domain:** Residues 907-1099. Contains the central portion of the RuvC domain. - **RuvC-III Domain:** Residues 1099-1368. Contains the C-terminal half of the RuvC domain, including the PAM-interacting (PI) domain. ### 2.2 Catalytic Sites and Metal Ion Coordination The HNH domain is responsible for cleaving the target (complementary) DNA strand. The catalytic site is composed of a conserved H-N-H motif, with key residues His840, Asn854, and His863. These residues coordinate a single Mg²⁺ ion, which activates a water molecule for nucleophilic attack on the scissile phosphate. The HNH domain is positioned in the ternary complex such that it is poised to cleave the target strand only after full R-loop formation and PAM recognition, ensuring specificity. The RuvC domain, split into three non-contiguous segments, is responsible for cleaving the non-target (non-complementary) strand. The catalytic tetrad is composed of Asp10, Glu762, His983, and Asp986. These residues coordinate two Mg²⁺ ions in a two-metal-ion mechanism, which is a hallmark of the RNase H family of nucleases. The RuvC domain is inactive in the apo state and only becomes catalytically competent upon a large conformational rearrangement that occurs upon sgRNA binding. ### 2.3 PAM-Interacting (PI) Domain The PI domain, located at the extreme C-terminus (residues 1099-1368), is the primary determinant of PAM specificity. For SpyCas9, the PI domain recognizes the 5'-NGG-3' PAM sequence on the non-target strand. The key residues involved in this recognition are Arg1333 and Arg1335, which form bidentate hydrogen bonds with the two guanine bases of the PAM. The Asn1315 residue interacts with the phosphate backbone. The PI domain undergoes a significant conformational change upon PAM binding, which is the initial trigger for the unwinding of the DNA duplex and the subsequent R-loop formation. ### 2.4 Interactive 3D Visualizer For a hands-on exploration of the Cas9 structure, including the spatial arrangement of the REC and NUC lobes, the catalytic residues, and the sgRNA-DNA heteroduplex, use the interactive visualizer below. This tool loads the high-resolution crystal structure (PDB: 4OO8) and allows for the visualization of secondary structure, surface electrostatics, and domain coloring. [Interactive 3D Protein Visualizer: Load cas9 (PDB: 4OO8)](/tools/protein-structure-viewer?source=direct&pdbId=4OO8) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The CRISPR-Cas Adaptive Immune Cascade The biological function of Cas9 is embedded within the three-stage CRISPR-Cas immune pathway: adaptation, expression, and interference. 1. **Adaptation:** Upon phage infection, the Cas1-Cas2 complex (and Csn2) integrates a short fragment of the foreign DNA into the CRISPR array as a new spacer. This process is not directly mediated by Cas9 but is essential for the memory of the infection. 2. **Expression:** The CRISPR array is transcribed into a long pre-crRNA. Concurrently, the tracrRNA gene is transcribed. The tracrRNA contains a region of complementarity to the direct repeats of the pre-crRNA, forming an RNA duplex. This duplex is recognized and cleaved by the host RNase III, with Cas9 acting as a scaffold to stabilize the complex. This processing yields mature crRNA-tracrRNA duplexes. 3. **Interference:** The mature crRNA-tracrRNA duplex is loaded into Cas9. The Cas9-ribonucleoprotein (RNP) complex then scans the cellular milieu for DNA sequences complementary to the crRNA spacer. The initial scanning is driven by PAM recognition. The PI domain of Cas9 transiently binds to PAM sequences, and if a PAM is found, the protein initiates local DNA melting. If the crRNA spacer is fully complementary to the target DNA (the protospacer), a stable R-loop is formed, triggering the conformational activation of the HNH and RuvC domains, leading to a blunt DSB. ### 3.2 R-Loop Formation and Conformational Dynamics The mechanism of target DNA unwinding and R-loop formation is a multi-step kinetic process. Initial PAM binding by the PI domain induces a conformational change in the bridge helix, which promotes the separation of the DNA strands at the PAM-proximal end. The crRNA seed region (nucleotides 10-12 of the spacer) then base-pairs with the target strand. This initial base-pairing is the critical kinetic checkpoint. If the seed region is fully complementary, the R-loop extends in a 5' to 3' direction along the target strand, displacing the non-target strand. The HNH domain, which is initially positioned far from the target strand, undergoes a large domain rotation (~30 Å) to engage the target strand. This movement is coupled with the repositioning of the RuvC domain, aligning the catalytic residues with the scissile phosphates. ### 3.3 Protein-Protein Interaction Networks While Cas9 functions primarily as a standalone enzyme, it interacts with several host factors. In *S. pyogenes*, Cas9 interacts with RNase III during crRNA maturation. It also interacts with the Cas1-Cas2 complex during the adaptation phase, although the exact nature of this interaction is still under investigation. In eukaryotic cells, when Cas9 is used as a genome-editing tool, it interacts with the endogenous DNA repair machinery, including Ku70/Ku80 (non-homologous end joining, NHEJ) and Rad51 (homology-directed repair, HDR). These interactions are not native but are critical for the downstream repair outcomes. ### 3.4 Mermaid Diagram: The Cas9 Interference Cascade ```mermaid sequenceDiagram participant Phage as "Bacteriophage DNA" participant Cas9 as "Cas9-sgRNA Complex" participant PAM as "PAM Sequence (NGG)" participant Rloop as "R-Loop Formation" participant HNH as "HNH Domain" participant RuvC as "RuvC Domain" participant DSB as "Double-Strand Break" Phage->>Cas9: Foreign DNA enters cell Cas9->>PAM: Scan for PAM (NGG) PAM-->>Cas9: PAM recognized (Arg1333/1335) Cas9->>Rloop: Local DNA melting & seed pairing Rloop-->>Cas9: Full complementarity confirmed Cas9->>HNH: Conformational activation Cas9->>RuvC: Conformational activation HNH->>DSB: Cleaves target strand (His840) RuvC->>DSB: Cleaves non-target strand (Asp10) Note over DSB: Blunt DSB 3bp upstream of PAM ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutations in the Bacterial Context In *S. pyogenes*, mutations in *cas9* can lead to a loss of CRISPR-Cas function, rendering the bacterium more susceptible to phage predation. However, in the clinical context of human infection, the loss of CRISPR-Cas function is often associated with increased acquisition of mobile genetic elements, including antibiotic resistance genes and virulence factors. For example, a frameshift mutation in *cas9* (a single adenine insertion at position 1234) has been identified in some clinical isolates of *S. pyogenes* M89, leading to a truncated, non-functional protein. This truncation is associated with the acquisition of a prophage encoding the streptococcal pyrogenic exotoxin A (SpeA), a superantigen linked to toxic shock syndrome. ### 4.2 Mutations in the Context of Genome Editing In the context of therapeutic genome editing, mutations in Cas9 are engineered to alter its function. These are not naturally occurring pathogenic mutations but are of clinical relevance. - **Catalytic Null Mutants (dCas9):** The D10A mutation in the RuvC domain and the H840A mutation in the HNH domain inactivate the nuclease activity while preserving DNA binding. This dead Cas9 (dCas9) is used for CRISPR interference (CRISPRi), CRISPR activation (CRISPRa), and base editing. These mutations are not pathogenic but are essential tools. - **PAM Specificity Mutants:** Mutations such as D1135E, R1335Q, and T1337R (the "SpCas9-HF" and "xCas9" variants) alter the PAM specificity from NGG to NGA or NG, expanding the targeting range. These mutations are designed to reduce off-target effects. - **Off-Target Associated Mutations:** Naturally occurring single-nucleotide polymorphisms (SNPs) in the human genome that are homologous to the sgRNA target site can lead to off-target cleavage. This is not a mutation in Cas9 itself but a consequence of the enzyme's tolerance for mismatches, particularly in the PAM-distal region of the spacer. ### 4.3 Clinical Differentials and Immunogenicity The primary clinical differential associated with SpyCas9 is its immunogenicity. A significant proportion of the human population has pre-existing antibodies against SpyCas9 due to prior exposure to *S. pyogenes* infections. A study by Charlesworth et al. (2019) found that 78% of healthy donors had anti-SpyCas9 antibodies, and 58% had anti-SpyCas9 T-cells. This pre-existing immunity poses a major hurdle for *in vivo* gene therapy, as the immune system may clear Cas9-expressing cells before they can effect the desired genomic modification. This has led to the development of alternative Cas9 orthologs from less common bacteria (e.g., *Staphylococcus aureus* Cas9, *Campylobacter jejuni* Cas9) that do not cross-react with the human immune system. --- ## 5. Host-Pathogen & Viral Interactions (If applicable) ### 5.1 Anti-CRISPR Proteins The most direct interaction between Cas9 and a viral factor is the family of anti-CRISPR (Acr) proteins. These are small proteins encoded by bacteriophages that inhibit the CRISPR-Cas system to allow for successful infection. For SpyCas9, several Acr proteins have been characterized: - **AcrIIA4:** This protein (from *[Listeria monocytogenes](/knowledge/bacteria/livestock-bacteria/listeria-monocytogenes-circling-disease-ruminants-silage)* prophage) binds to the PAM-interacting domain of Cas9, mimicking the PAM duplex and preventing DNA binding. It acts as a molecular mimic, occupying the PAM-binding cleft and sterically blocking the interaction with the target DNA. - **AcrIIA5:** This protein inhibits Cas9 by a different mechanism, likely by interfering with the conformational activation of the HNH domain. It does not block DNA binding but prevents the cleavage step. - **AcrIIC1:** This protein binds to the HNH domain and directly inhibits its catalytic activity. These Acr proteins are of significant clinical interest. They can be used to create "off-switches" for Cas9-based genome editing, allowing for temporal control of editing activity and reducing off-target effects. ### 5.2 Prophage-Encoded Virulence Factors The interaction between Cas9 and phages is not limited to inhibition. The loss of Cas9 function, as described in Section 4.1, can lead to the lysogenic integration of prophages carrying virulence genes. This is a classic example of host-pathogen co-evolution, where the selective pressure of phage predation drives the inactivation of the bacterial immune system, with the trade-off of acquiring virulence traits. --- ## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors ### 6.1 Cas9 as a Therapeutic Target In the context of bacterial infections, Cas9 is not a direct drug target. However, the CRISPR-Cas system itself is being explored as a sequence-specific antimicrobial. This approach, known as "CRISPR-Cas antimicrobials," uses a Cas9 nuclease delivered via a phage or conjugative plasmid to target and cleave antibiotic resistance genes or essential bacterial genes, leading to bacterial cell death. This is a promising strategy for eliminating specific bacterial strains from a mixed population without disrupting the microbiome. ### 6.2 Small-Molecule Inhibitors of Cas9 For genome editing applications, small-molecule inhibitors of Cas9 are being developed to reduce off-target effects. These inhibitors can be divided into two classes: 1. **Nuclease Activity Inhibitors:** These molecules bind to the catalytic sites (HNH or RuvC) and block cleavage. For example, the compound **BRD0539** was identified in a high-throughput screen as a small molecule that binds to the HNH domain and inhibits its activity. It does not prevent DNA binding but blocks the cleavage step, allowing for the formation of a stable R-loop without a DSB. 2. **DNA Binding Inhibitors:** These molecules compete with the sgRNA or the target DNA for binding to Cas9. The compound **NCGC-00029283** binds to the REC lobe and prevents the loading of the sgRNA, thereby inhibiting all downstream activity. ### 6.3 Gene Therapy Vectors The most significant clinical application of Cas9 is in gene therapy. The *cas9* gene is delivered to target cells via viral vectors, primarily adeno-associated viruses (AAVs) and lentiviruses. The large size of the SpyCas9 gene (4.1 kb) poses a packaging challenge for AAV, which has a cargo limit of ~4.7 kb. This has led to the development of smaller Cas9 orthologs (e.g., SaCas9, 3.2 kb) and the use of dual-AAV systems where the Cas9 gene is split into two halves and reconstituted via intein splicing. Several clinical trials are underway using Cas9-based therapies for conditions such as sickle cell disease, beta-thalassemia, and Leber congenital amaurosis. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides the essential database accessions for the *cas9* gene and its protein product. | **Database** | **Identifier** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 901176 | Gene ID for *cas9* in *S. pyogenes* M1 GAS | | **NCBI Nucleotide** | NC_002737.2 | Complete genome sequence of *S. pyogenes* M1 GAS | | **Ensembl Bacteria** | Not applicable | *cas9* is not a eukaryotic gene; use NCBI | | **UniProt** | Q99ZW2 | Primary protein sequence and annotation | | **RCSB PDB** | 4OO8 | Crystal structure of SpyCas9 in complex with sgRNA and target DNA | | **RCSB PDB** | 4UN3 | Crystal structure of SpyCas9 in the apo state | | **RCSB PDB** | 5F9R | Crystal structure of SpyCas9 with a catalytically dead HNH domain | | **Gene Ontology (GO)** | GO:0004519 | Endonuclease activity | | **Gene Ontology (GO)** | GO:0003677 | DNA binding | | **Gene Ontology (GO)** | GO:0043571 | RNA-guided DNA cleavage | | **STRING** | 1314.Spy_1046 | Protein-protein interaction network for SpyCas9 | | **BioGRID** | Not applicable | No curated interactions for bacterial Cas9 | | **ClinVar** | Not applicable | No human pathogenic variants; bacterial gene | | **Addgene** | 42230 | Plasmid encoding SpyCas9 for mammalian expression | --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References The following references are cited in the text and provide the foundational literature for the structure, function, and clinical applications of Cas9. [1] Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*, 337(6096), 816-821. [https://doi.org/10.1126/science.1225829](https://doi.org/10.1126/science.1225829) [2] Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., ... & Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. *Cell*, 156(5), 935-949. [https://doi.org/10.1016/j.cell.2014.02.001](https://doi.org/10.1016/j.cell.2014.02.001) [3] Anders, C., Niewoehner, O., Duerst, A., & Jinek, M. (2014). Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. *Nature*, 513(7519), 569-573. [https://doi.org/10.1038/nature13579](https://doi.org/10.1038/nature13579) [4] Jiang, F., Zhou, K., Ma, L., Gressel, S., & Doudna, J. A. (2015). A Cas9-guide RNA complex preorganized for target DNA recognition. *Science*, 348(6242), 1477-1481. [https://doi.org/10.1126/science.aab1452](https://doi.org/10.1126/science.aab1452) [5] Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., & Doudna, J. A. (2014). DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. *Nature*, 507(7490), 62-67. [https://doi.org/10.1038/nature13011](https://doi.org/10.1038/nature13011) [6] Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., ... & Porteus, M. H. (2019). Identification of preexisting adaptive immunity to Cas9 proteins in humans. *Nature Medicine*, 25(2), 249-254. [https://doi.org/10.1038/s41591-018-0326-x](https://doi.org/10.1038/s41591-018-0326-x) [7] Pawluk, A., Amrani, N., Zhang, Y., Garcia, B., Hidalgo-Reyes, Y., Lee, J., ... & Davidson, A. R. (2016). Naturally occurring off-switches for CRISPR-Cas9. *Cell*, 167(7), 1829-1838. [https://doi.org/10.1016/j.cell.2016.11.017](https://doi.org/10.1016/j.cell.2016.11.017) [8] Maji, B., Gangopadhyay, S. A., Lee, M., Shi, M., Wu, P., Heler, R., ... & Bhatt, A. S. (2019). A high-throughput platform to identify small-molecule inhibitors of CRISPR-Cas9. *Cell*, 177(4), 1067-1079. [https://doi.org/10.1016/j.cell.2019.04.009](https://doi.org/10.1016/j.cell.2019.04.009) [9] Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., ... & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science*, 339(6121), 819-823. [https://doi.org/10.1126/science.1231143](https://doi.org/10.1126/science.1231143) [10] Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., ... & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. *Science*, 339(6121), 823-826. [https://doi.org/10.1126/science.1232033](https://doi.org/10.1126/science.1232033) [11] Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., ... & Charpentier, E. (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature*, 471(7340), 602-607. [https://doi.org/10.1038/nature09886](https://doi.org/10.1038/nature09886) [12] Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012). Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proceedings of the National Academy of Sciences*, 109(39), E2579-E2586. [https://doi.org/10.1073/pnas.1208507109](https://doi.org/10.1073/pnas.1208507109)